Iris Pharma, a France-based, ophthalmology-focused CRO that offers preclinical and clinical drug/device development services, and Oculos Clinical Research, a Tampa, Fla.-based full-service CRO specializing in ophthalmology, have formed a strategic alliance.

Both companies provide drug formulation services through all phases of clinical trials in all ocular pathologies, including glaucoma, dry eye, anti-inflammatory and age-related macular degeneration.

“We have a lot of confidence in Oculos’ wide range of quality services for ophthalmic drug and device development. We are excited to work with the Oculos team, and to intensify our integrated preclinical and clinical development services capacity to support FDA and EMA submissions of ocular products,” said Yann Quentric, head of business development at Iris Pharma.